WALTHAM, Mass.--( BUSINESS WIRE )--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has elected Mr. Steven L. Hoerter, Chief Commercial Officer at Agios Pharmaceuticals, Inc., to its Board of Directors, effective as of May 17, 2018. Mr. Hoerter will serve as an independent director and a member of the Nominating and Corporate Governance Committee. The number of Deciphera directors was increased from eight to nine in connection with Mr. Hoerter's election. "We are delighted to welcome Steve to our Board of Directors, and we value the expertise he brings to Deciphera at this strategically important time in the evolution of the Company," stated Michael D. Taylor, Ph.D., President and Chief Executive Officer of Deciphera Pharmaceuticals. "Mr.